Brokers Offer Predictions for TSE:PRN FY2028 Earnings

Profound Medical Corp. (TSE:PRN) – Investment analysts at Raymond James issued their FY2028 EPS estimates for Profound Medical in a research report issued to clients and investors on Thursday, November 7th. Raymond James analyst R. Sarugaser anticipates that the company will earn $4.11 per share for the year. The consensus estimate for Profound Medical’s current full-year earnings is ($1.90) per share.

Profound Medical Price Performance

Shares of PRN opened at C$11.32 on Monday. The firm has a market capitalization of C$277.11 million, a PE ratio of -6.82 and a beta of 0.81. The company’s 50-day moving average is C$10.73 and its 200-day moving average is C$11.55. Profound Medical has a fifty-two week low of C$9.55 and a fifty-two week high of C$16.00. The company has a debt-to-equity ratio of 16.95, a current ratio of 8.61 and a quick ratio of 14.98.

Insider Activity

In other Profound Medical news, Senior Officer Rashed Osman Dewan purchased 9,765 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The shares were acquired at an average cost of C$12.85 per share, for a total transaction of C$125,480.25. Insiders own 8.62% of the company’s stock.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.